Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer Ireland

NICE Knockback For BMS Immunotherapy Opdivo In Lung Cancer

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb Co.'s immunotherapy Opdivo (nivolumab) is not cost-effective and should not be provided for NHS patients with lung cancer in England and Wales, according to draft guidance from the health technology assessment body NICE. BMS had offered a confidential discounting scheme to reduce the cost below its list price of £5,200 per month (for a patient weighing 73kg), but this failed to sway the National Institute for Health and Care Excellence.

Table

View full table

Topics

Tags:
Cancer Ireland
Latest Headlines

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

See All
UsernamePublicRestriction

Register

SC063994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By